AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Hemophilia

Recent research efforts aimed at curing Hemophilia.

Last updated
Also available in
Français — Hémophilie

Hemophilia

Overview

Hemophilia is an inherited bleeding disorder in which the blood lacks enough working clotting factor VIII (hemophilia A) or factor IX (hemophilia B). This can cause prolonged bleeding after injury or surgery and, in more severe disease, spontaneous bleeding—especially into joints and muscles—which can produce chronic pain and permanent joint damage. Hemophilia is lifelong, but early, comprehensive care has greatly improved outcomes. WFH management guidelines (onlinelibrary.wiley.com)

The present standard of care is preventive treatment (“prophylaxis”) with infused factor VIII or IX replacement, supplemented in eligible patients by non-factor medicines that improve clotting. Treatment also includes rapid management of breakthrough bleeds, monitoring and treatment of inhibitors—antibodies that neutralize replacement factor—and coordinated care through hemophilia treatment centers. WFH management guidelines FDA Roctavian approval (guidelines.wfh.org)

Scope of Recent Research (2020–present)

Research since 2020 has shifted hemophilia from a disease managed by repeated prophylaxis toward one in which a single intervention can produce the patient’s own clotting factor for years. The dominant questions are now durability of expression, immune and liver safety, eligibility for people with pre-existing antibodies to delivery vectors, inclusion of children and people with inhibitors, and whether permanent gene editing can eventually improve on gene addition. Two hemophilia gene therapies have established multi-year clinical benefit, but the evidence supports describing them as potentially disease-modifying functional treatments—not confirmed lifetime cures. Five-year HOPE-B results Five-year GENEr8-1 results (nejm.org)

Major Breakthroughs and Emerging Therapies

The major clinical breakthrough has been liver-directed adeno-associated virus (AAV) gene addition. AAV is a modified viral delivery vehicle that carries a working clotting-factor gene into liver cells, enabling them to release factor VIII or IX into blood. In hemophilia A, valoctocogene roxaparvovec (Roctavian) was approved in the United States in June 2023 for eligible adults with severe disease. In the final five-year phase 3 GENEr8-1 analysis, treated-bleed rates in the rollover population were 83.3% lower than baseline and factor VIII infusion use was 94.9% lower; however, monitoring of long-term factor VIII expression remains essential. FDA Roctavian approval Five-year GENEr8-1 results (fda.gov)

Hemophilia B has produced the most persuasive durability data so far. Etranacogene dezaparvovec (Hemgenix) uses AAV5 to deliver a high-activity version of factor IX called FIX-Padua. In the final five-year HOPE-B phase 3 report, mean factor IX activity was 36.1 IU/dL at year five, annualized bleeding fell 63% versus the lead-in period, and routine or bleed-treatment factor IX use fell 96%. The U.S. FDA approved Hemgenix in November 2022 and updated its prescribing information after the completed HOPE-B study in April 2026. Five-year HOPE-B results FDA Hemgenix information (nejm.org)

A second hemophilia B AAV therapy, fidanacogene elaparvovec (Beqvez), achieved a 71% reduction in annualized bleeding in its phase 3 trial and received U.S. approval in April 2024 for selected adults. Its commercial history also demonstrates that regulatory approval does not guarantee durable access: Pfizer decided in February 2025 to terminate development and commercialization, and the European Union authorization was withdrawn on May 15, 2025. Phase 3 fidanacogene trial FDA Beqvez information Pfizer 2024 annual report EMA Beqvez record (nejm.org)

Gene editing is the important experimental route toward a more literal cure. Rather than adding a separate factor gene, CRISPR-based systems aim to repair a mutation or insert a therapeutic gene at a planned genomic site. In a 2024 hemophilia A mouse study, lipid nanoparticles carrying Cas9 messenger RNA and guide RNA corrected a frameshift mutation in liver sinusoidal endothelial cells—the cells that normally make much of the body’s factor VIII—producing factor VIII activity up to 6% for 26 weeks. This remains preclinical, but it offers a nonviral, transient-delivery strategy that could avoid persistent nuclease expression. LNP-CRISPR hemophilia A study (pubmed.ncbi.nlm.nih.gov)

Other preclinical work is trying to make hemophilia A gene therapy more durable and lower-dose. An engineered factor VIII variant resistant to inactivation by activated protein C restored hemostasis in hemophilia A mice at below-normal expression levels, potentially reducing the AAV dose required. NIH-funded investigators are also testing mutation-specific small molecules that may promote readthrough of certain premature stop mutations or improve folding and secretion of defective factor VIII, although these approaches are not yet curative clinical treatments. Enhanced factor VIII study NIH hemophilia A therapeutics award (pubmed.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

The completed phase 3 HOPE-B trial enrolled 67 adults with severe or moderately severe hemophilia B and tested one intravenous dose of etranacogene dezaparvovec; the ClinicalTrials.gov record was updated in March 2026 as completed. Its five-year peer-reviewed results provide the strongest current evidence that one-time factor IX gene addition can sustain clinically meaningful bleed protection for at least five years. HOPE-B trial record Five-year HOPE-B results (clinicaltrials.gov)

For hemophilia A, BioMarin’s phase 3 GENEr8-1 trial studied a single Roctavian infusion in 134 adult men with severe hemophilia A without inhibitors; 128 completed the study after a median follow-up of approximately five years. Participants may enter the GENEr8-LTE long-term extension study, which was enrolling by invitation as of its January 2026 update. GENEr8-1 trial record GENEr8-1 five-year results GENEr8-LTE trial record (clinicaltrials.gov)

The most consequential experimental trials to watch are therefore not only new AAV vectors but also studies that broaden eligibility, lower vector dose, improve factor VIII durability, or move gene editing from animal models into carefully monitored first-in-human testing. Long-term registries will be necessary because rare late effects, durability beyond five to ten years, and outcomes after loss of factor expression cannot be answered by short pivotal trials. WFH Gene Therapy Registry (wfh.org)

Methodologies and Scientific Approaches

Researchers measure whether an intervention is approaching a functional cure through factor VIII or IX activity, annualized bleeding rate, use of replacement factor, joint outcomes, quality of life, liver enzymes, immune responses, and adverse events. AAV studies generally deliver factor genes intravenously to the liver; eligibility and safety assessment include testing for neutralizing antibodies against the AAV capsid, because prior immunity can block delivery. FDA Roctavian approval FDA Beqvez information (fda.gov)

Preclinical programs use hemophilia mice, cell-based factor-expression assays, genomic sequencing for on-target and off-target editing, clotting tests such as activated partial thromboplastin time, and bleeding-challenge models. Delivery platforms being compared include AAV vectors, lipid nanoparticles carrying messenger RNA, plasmid DNA, and engineered factor variants that produce more clotting activity per unit of gene expression. CRISPR correction in hemophilia A mice LNP-CRISPR hemophilia A study Enhanced factor VIII study (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

Clinical translation has been driven by BioMarin, CSL Behring, Pfizer, and their multinational trial networks, alongside academic centers including the Children’s Hospital of Philadelphia, the University of Pennsylvania, the University of Washington, Seattle Children’s Research Institute, and Cleveland Clinic/Case Western Reserve University. The latter received an NHLBI award totaling $1,036,148 across fiscal years 2024 and 2025 for work on factor VIII expression, small-molecule rescue strategies, and higher-expression factor VIII variants. NIH hemophilia A therapeutics award Enhanced factor VIII study LNP-CRISPR hemophilia A study (taggs.hhs.gov)

Patient organizations are central to post-treatment evidence generation and research priorities. The World Federation of Hemophilia launched enrollment in its international Gene Therapy Registry in October 2024, while the National Bleeding Disorders Foundation reported a $22 million investment in research toward cures for inherited bleeding disorders and funded hemophilia-focused work on inhibitors and biomarkers. WFH Gene Therapy Registry launch NBDF research fellowships (wfh.org)

Strengths, Limitations, and Challenges

The strongest result is that a single infusion can substantially reduce bleeding and the need for routine factor replacement for years, particularly in hemophilia B. This can reduce treatment burden and may protect joints if sustained. However, AAV gene addition is not the same as correcting every affected cell or passing a repaired gene to future children; expression can decline, particularly in hemophilia A, and a person who loses expression may again need prophylaxis. Five-year HOPE-B results Five-year GENEr8-1 results (nejm.org)

Important constraints include liver inflammation requiring corticosteroids or other immunosuppression, pre-existing anti-AAV antibodies, uncertain suitability for children, limited evidence in people with inhibitors or significant liver disease, inability to simply redose the same AAV vector, and the need for long-term surveillance for potential liver and genomic safety concerns. Access is also a scientific and practical challenge: a product can be licensed yet commercially withdrawn, as illustrated by Beqvez. FDA Roctavian approval EMA Beqvez record (fda.gov)

Outlook and Future Directions

As of August 8, 2026, hemophilia B is closest to a durable functional cure: the key milestone is whether factor IX expression, low bleeding rates, and safety remain favorable beyond the existing five-year phase 3 evidence. For hemophilia A, the next milestones are durable factor VIII expression at lower AAV doses, broader eligibility, and confirmation that engineered factors improve persistence. A permanent molecular cure through gene editing is scientifically plausible but remains preclinical; before it can be considered clinically curative, it must demonstrate precise delivery, durable correction, acceptable off-target risk, and long-term safety in people. Five-year HOPE-B results LNP-CRISPR hemophilia A study (nejm.org)

References

Don't see your disease? Request a report